Sphingolipid modulation: A strategy for cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 285-302

  Delgado, Antonio ^a,b   Fabriàs, Gemma ^a   Bedia, Carmen ^a   Casas, Josefina ^a   Abad, José Luis ^a  

^a CSIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Analogs; Enzyme inhibitors; Metabolism; Modulation; Sphingolipids

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CERAMIDASE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE KINASE; CURCUMIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; FINGOLIMOD; FUMONISIN B1; GAMMA TOCOPHEROL; GEMCITABINE; GENISTEIN; GW 4869; IRINOTECAN; N OLEOYLETHANOLAMINE; PACLITAXEL; RESVERATROL; SAFINGOL; SG 12; SG 14; SMA 7; SORAFENIB; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCRISTINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME MODIFICATION; HOMEOSTASIS; HUMAN; LEUKEMIA CELL LINE; LIPID METABOLISM; LIPOGENESIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; TUMOR GROWTH;

EID: 84860505102     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228643     Document Type: Article

References (215)

1. Futerman, A. H.; Hannun, Y. A. The complex life of simple sphingolipids, EMBO Rep., 2004, 5, 777-782.
2. Hannun, Y. A.; Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids, Nat. Rev. Mol. Cell Biol., 2008, 9, 139-150.
3. Fyrst, H.; Saba, J. D. An update on sphingosine-1-phosphate and other sphingolipid mediators, Nat. Chem. Biol., 2010, 6, 489-497.
4. T. Kolter, A view on sphingolipids and disease, Chem. Phys. Lipids, 2011, 164, 590-606.
5. Ryland, L. K.; Fox, T. E.; Liu, X.; Loughran, T. P.; Kester, M.; Dysregulation of sphingolipid metabolism in cancer, Cancer Biol. Ther.,11(2), 2011, 138-149.
6. Patwardhan, G. A.; Liu, Y.; Sphingolipids and expression regulation of genes in cancer, Prog. Lipid Res., 2011, 50, 104-114.
7. Reynolds, C. P.; Maurer, B. J.; Kolesnick, R. N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett., 2004, 206, 169-180.
8. Saddoughi, S. A.; Song, P.; Ogretmen, B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell. Biochem., 2008, 49, 413-440.
9. Wang, H.; Giuliano, A. E.; Cabot, M. C. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol. Cancer Ther., 2002, 1, 719-726.
10. Morjani, H.; Madoulet, C.; Immunosuppressors as multidrug resistance reversal agents. Methods Mol. Biol., 2010, 596, 433-446.
11. Sauane, M.; Su, Z. Z.; Dash, R.; Liu, X.; Norris, J. S.; Sarkar, D.; Lee, S. G.; Allegood, J. C.; Dent, P.; Spiegel, S.; Fisher, P. B. Ceramide plays a prominent role in MDA-7/IL-24-induced cancerspecific apoptosis. J. Cell Physiol., 2010, 222, 546-555.
12. Levy, M.; Futerman, A. H. Mammalian ceramide synthases. IUBMB Life, 2010, 62, 347-356.
13. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicininduced apoptosis: an alternative mechanism for generating death signals. Cell, 1995, 82, 405-414.
14. Fabrias, G.; Munoz-Olaya, J. M.; Cingolani, F.; Signorelli, P.; Casas, J.; Gagliostro, V.; Ghidoni, R. Dihydroceramide desaturase and dihydrosphingolipids: Debutant players in the sphingolipid arena, Prog. Lipid Res., 2011, 0000.
15. Rahmaniyan, M.; Curley, R. W.; Obeid, Jr., L. M.; Hannun, Y. A.; Kraveka, J. M. Identification of Dihydroceramide desaturase as a direct in vitro target for fenretinide, J. Biol. Chem., 2011, 286, 24754-24764.
16. Signorelli, P.; Munoz-Olaya, J. M.; Gagliostro, V.; Casas, J.; Ghidoni, R.; Fabrias, G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells, Cancer Lett., 2009, 282, 238-243.
17. Delgado, A.; Casas, J.; Llebaria, A., Abad J. L.; Fabrias, G. Chemical Tools to investigate sphingolipid metabolism and functions. Chem. Med. Chem., 2007, 2, 580-606.
18. Delgado, A.; Casas, J.; Llebaria, A.; Abad, J. L.; Fabrias, G. Inhibitors of sphingolipid metabolism enzymes, Biochim. Biophys. Acta-Biomembranes, 2006, 1758, 1957-1977.
19. Brodesser, S. Kolter, T. Dihydroceramide desaturase inhibition by a cyclopropanated dihydroceramide analog in cultured keratinocytes, J. Lipids, 2011, 2011, 724015.
20. Triola, G.; Fabriàs, G.; Llebaria, A. Synthesis of a cyclopropene analogue of ceramide, a potent inhibitor of dihydroceramide desaturase, Angew. Chem. Int. Ed., 2001, 40, 1960-1962.
21. Triola, G.; Fabrias, G.; Casas, J.; Llebaria, A. Synthesis of cyclopropene analogues of ceramide and their effect on dihydroceramide desaturase, J. Org. Chem., 2003, 68, 9924-9932.
22. Triola, G.; Fabrias, G.; Dragusin, M.; Niederhausen, L.; Broere, R.; Llebaria, A.; van Echten-Deckert, G. Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl] octanamide (GT11) in primary cultured cerebellar neurons, Mol. Pharmacol., 2004, 66, 1671-1678.
23. Jiang, Q.; Wong, J.; Fyrst, H.; Saba, J. D.; Ames, B. N. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis, Proc. Natl. Acad. Sci. USA, 2004, 101, 17825-17830.
24. Zheng, W. Phenretinide (4-hydroxyphenylretinamide) increases dihydroceramide and dihydrosphingolipids due to inhibition of dihydroceramide desaturase, Atlanta: Georgia Institute of Technology, 2006.
25. Hsieh, T. C.; Wu, J. M. Resveratrol: Biological and pharmaceutical properties as anticancer molecule, Biofactors 2010, 36, 360-369.
26. Hanada, K.; Kumagai, K.; Tomishige, N.; Yamaji, T. CERTmediated trafficking of ceramide, Biochim. Biophys. Acta, 2009, 1791, 684-691.
27. Yasuda, S.; Kitagawa, H.; Ueno, M.; Ishitani, H.; Fukasawa, M.; Nishijima, M.; Kobayashi, S.; Hanada, K. A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis, J. Biol. Chem., 2001, 276, 43994-44002.
28. Nakamura, Y.; Matsubara, R.; Kitagawa, H.; Kobayashi, S.; Kumagai, K.; Yasuda, S.; Hanada, K. Stereoselective synthesis and structure-activity relationship of novel ceramide trafficking inhibitors. (1R,3R)-N-(3-hydroxy-1-hydroxymethyl-3phenylpropyl) dodecanamide and its analogues, J. Med. Chem., 2003, 46, 3688-3695.
29. Duris, A.; Wiesenganger, T.; Moravcikova, D.; Baran, P.; Kozisek, J.; Daich, A.; Berkes, D. Expedient and practical synthesis of CERT-Dependent ceramide trafficking inhibitor HPA-12 and its analogues, Org. Lett., 2011, 13, 1642-1645.
30. Kudo, N.; Kumagai, K.; Matsubara, R.; Kobayashi, S.; Hanada, K.; Wakatsuki, S.; Kato, R. Crystal structures of the CERT START domain with inhibitors provide insights into the mechanism of ceramide transfer, J. Mol. Biol., 2010, 396, 245-251.
31. Swanton, C.; Marani, M.; Pardo, O.; Warne, P. H.; Kelly, G.; Sahai, E.; Elustondo, F.; Chang, J.; Temple, J.; Ahmed, A. A. Brenton, J. D.; Downward, J.; Nicke, B. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 2007, 11, 498-512.
32. Gangoiti, P.; Camacho, L.; Arana, L.; Ouro, A.; Granado, M. H.; Brizuela, L.; Casas, J.; Fabrias, G.; Abad, J. L.; Delgado, A.; Gomez-Munoz, A. Control of metabolism and signaling of simple bioactive sphingolipids: implications in disease. Prog. Lipid Res., 2010, 49, 316-334.
33. Fabrias, G.; Bedia, C.; Casas, J.; Abad, J. L.; Delgado, A. Ceramidases in hematological malignancies: senseless Or neglected target? Anticancer Agents Med. Chem., 2011, 11(9), 830-843.
34. Zeidan, Y. H.; Jenkins, R. W.; Korman, J. B.; Liu, X.; Obeid, L. M.; Norris, J. S.; Hannun, Y. A. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr. Drug Targets, 2008, 9, 653-661.
35. Park, J. H.; Schuchman, E. H. Acid ceramidase and human disease. Biochim. Biophys. Acta, 2006, 1758, 2133-2138.
36. Duan, R. D.; Nilsson, A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development, Prog Lipid Res., 2009, 48, 62-72.
37. Elojeimy, S.; Liu, X.; McKillop, J. C.; El-Zawahry, A. M.; Holman, D. H.; Cheng, J. Y.; Meacham, W. D.; Mahdy, A. E. M.; Saad, A. F.; Turner, L. S.; Cheng, J.; Day, T. A.; Dong, J.-Y.; Bielawska, A.; Hannun, Y. A.; Norris, J. S. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy, Mol. Ther., 2007, 15, 1259-1263.
38. Seelan, R. S.; Qian, C.; Yokomizo, A.; Bostwick, D. G.; Smith, D. I.; Liu, W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Gene. Chromosomes Canc., 2000, 29, 137-146.
39. Perry, D. K.; Carton, J.; Shah, A. K.; Meredith, F.; Uhlinger, D. J.; Hannun, Y. A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis, J. Biol. Chem., 2000, 275, 9078-9084.
40. Ruckhaberle, E.; Holtrich, U.; Engels, K.; Hanker, L.; Gatje, R.; Metzler, D.; Karn, T.; Kaufmann, M.; Rody, A. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric, 2009, 1-12.
41. Saad, A. F.; Meacham, W. D.; Bai, A.; Anelli, V.; Elojeimy, S.; Mahdy, A. E.; Turner, L. S.; Cheng, J.; Bielawska, A.; Bielawski, J.; Keane, T. E.; Obeid, L. M.; Hannun, Y. A.; Norris, J. S.; Liu, X. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol. Ther., 2007, 6, 1455-1460.
42. Sugita, M.; Williams, M.; Dulaney, J. T.; Moser, H. W. Ceramidase and ceramide synthesis in human kidney and cerebellum - description of a new alkaline ceramidase. Biochim. Biophys. Acta, 1975, 398, 125-131.
43. Selzner, M.; Bielawska, A.; Morse, M. A.; Rudiger, H. A.; Sindram, D.; Hannun, Y. A.; Clavien, P. A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001, 61, 1233-1240.
44. Raisova, M.; Goltz, G.; Bektas, M; Bielawska, A.; Riebeling, C.; Hossini, A. M.; Eberle, J.; Hannun, Y. A.; Orfanos, C. E.; Geilen, C. C. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes, FEBS Lett., 2002, 516, 47-52.
45. Samsel, L.; Zaidel, G.; Drumgoole, H. M.; Jelovac, D.; Drachenberg, C.; Rhee, J. G.; Brodie, A. M.; Bielawska, A.; Smyth, M. J.; The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts, Prostate, 2004, 58, 382-393.
46. Szulc, Z. M.; Mayroo, N.; Bai, A.; Bielawski, J.; Liu, X.; Norris, J. S.; Hannun, Y. A.; Bielawska, A. Novel analogs of d-e-MAPP and B13. Part 1: Synthesis and evaluation as potential anticancer agents. Bioorg. Med. Chem., 2008, 16, 1015-1031.
47. Bielawska, A.; Bielawski, J.; Szulc, Z. M.; Mayroo, N.; Liu, X.; Bai, A.; Elojeimy, S.; Rembiesa, B.; Pierce, J.; Norris, J. S.; Hannun, Y. A. Novel analogs of d-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids. Bioorg. Med. Chem., 2008, 16, 1032-1045.
48. Kim, Y. J.; Kim, E. A.; Sohn, U. D.; Yim, C. B.; Im, C. Cytotoxic activity and structure activity relationship of ceramide analogues in Caki-2 and HL-60 Cells. Korean J. Physiol. Pharmacol., 2010, 14, 441-447.
49. Proksch, D.; Klein, J. J.; Arenz, C. Potent inhibition of acid ceramidase by novel B-13 analogues. J. Lipids, 2011, 971618.
50. Holman, D. H.; Turner, L. S.; El-Zawahry, A.; Elojeimy, S.; Liu, X.; Bielawski, J.; Szulc, Z. M.; Norris, K.; Zeidan, Y. H.; Hannun, Y. A.; Bielawska, A.; Norris, J. S. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol., 2008, 61, 231-242.
51. Granot, T.; Milhas, D.; Carpentier, S.; Dagan, A.; Segui, B.; Gatt, S.; Levade, T. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia, 2006, 20, 392-399.
52. Mahdy, A. E.; Cheng, J. C.; Li, J.; Elojeimy, W. D.; Meacham, L.; Turner, S.; Bai, A.; Gault, C. R.; McPherson, A. S.; Garcia, N.; Beckham, T. H.; Saad, A.; Bielawska, A.; Bielawski, J.; Hannun, Y. A.; Keane, T. E.; Taha, M. I.; Hammouda, H. M.; Norris, J. S.; Liu, X. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol. Ther., 2009, 17, 430-438.
53. Bai, A.; Szulc, Z. M.; Bielawski, J.; Mayroo, N.; Liu, X.; Norris, J.; Hannun, Y. A.; Bielawska, A. Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg. Med. Chem., 2009, 17, 1840-1848.
54. Bielawska, A.; Greenberg, M. S.; Perry, D.; Jayadev, S.; Shayman, J. A.; McKay, C.; Hannun, Y. A. (1S,2R)-D-erythro-2-(Nmyristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J. Biol. Chem., 1996, 271, 12646-12654.
55. Qin, J. D.; Weiss, L.; Slavin, S.; Gatt, S.; Dagan, A. Synthetic, nonnatural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice. Cancer Invest., 2010, 28, 535-543.
56. Bedia, C.; Triola, G.; Casas, J.; Llebaria, A.; Fabrias, G. Analogs of the dihydroceramide desaturase inhibitor GT11 modified at the amide function: synthesis and biological activities. Org. Biomol. Chem., 2005, 3, 3707-3712.
57. Grijalvo, S.; Bedia, C.; Triola, G.; Casas, J.; Llebaria, A.; Teixido, J.; Rabal, O.; Levade, T.; Delgado, A.; Fabrias, G. Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues. Chem. Phys. Lipids, 2006, 144, 69-84.
58. Bedia, C.; Canals, D.; Matabosch, X.; Harrak, Y.; Casas, J.; Llebaria, A.; Delgado, A.; Fabrias, G. Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem. Phys. Lipids, 2008, 156, 33-40.
59. Abad, J. L.; Fabrias, G.; Casas, J.; Garrido, M.; Camacho, L.; Simbari, F.; Delgado, A. Derivados de aminoetanol sustituidos en C2 y su uso como antitumorales. 2010, Spanish Patent P201031642.
60. Senkal, C. E.; Ponnusamy, S.; Rossi, M. J.; Sundararaj, K.; Szulc, Z.; Bielawski, J.; Bielawska, A.; Meyer, M.; Cobanoglu, B.; Koybasi, S.; Sinha, D.; Day, T. A.; Obeid, L. M.; Hannun, Y. A.; Ogretmen, B. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 317, 1188-1199.
61. Separovic, D.; Saad, Z. H.; Edwin, E. A.; Bielawski, J.; Pierce, J. S.; Buren, E. V.; Bielawska, A. C16-Ceramide analog combined with Pc 4 photodynamic therapy evokes enhanced total ceramide accumulation, promotion of DEVDase activation in the absence of apoptosis, and augmented overall cell killing. J. Lipids, 2011, 2011, 713867.
62. Separovic, D.; Joseph, N.; Breen, P.; Bielawski, J.; Pierce, J. S.; Buren, E. V.; Bhatti, G.; Saad, Z. H.; Bai, A.; Bielawska, A. Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitization. Biochem. Biophys. Res. Commun., 2011, 409, 372-377.
63. Gouaze-Andersson, V.; Flowers, M.; Karimi, R.; Fabrias, G.; Delgado, A.; Casas, J.; Cabot, M. C. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate, 2011, 71, 1064-1073.
64. Lucki, N. C.; Sewer, M. B. Genistein stimulates MCF-7 Breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J. Biol. Chem., 2011, 286, 19399-19409.
65. Liu, H.; Sugiura, M.; Nava, V. E.; Edsall, L. C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama, T.; Spiegel, S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem., 2000, 275, 19513-19520.
66. Kihara, A.; Anada, Y.; Igarashi, Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. J. Biol. Chem., 2006, 281, 4532-4539.
67. Venkataraman, K.; Thangada, S.; Michaud, J.; Oo, M. L.; Ai, Y.; Lee, Y. M.; Wu, M.; Parikh, N. S.; Khan, F.; Proia, R. L.; Hla, T. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J., 2006, 397, 461-471.
68. Pyne, S.; Lee, S. C.; Long, J.; Pyne, N. J. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal, 2009, 21, 14-21.
69. Spiegel, S.; Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol, 2011, 11, 403-415.
70. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S.; Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381, 800-803.
71. Cuvillier, O.; Ader, I.; Bouquerel, P.; Brizuela, L.; Malavaud, B.; Mazerolles, C.; Rischmann, P. Activation of sphingosine Kinase-1 in cancer: implications for therapeutic targeting. Curr. Mol. Pharmacol., 2010, 3, 53-65.
72. Cuvillier, O. Sphingosine kinase-1--a potential therapeutic target in cancer. Anticancer Drugs, 2007, 18, 105-110.
73. Hait, N. C.; Oskeritzian, C. A.; Paugh, S. W.; Milstien, S.; Spiegel, S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta Biomembr., 2006, 1758, 2016-2026.
74. Xia, P.; Gamble, J. R.; Wang, L.; Pitson, S. M.; Moretti, P. A.; Wattenberg, B. W.; D'Andrea, R. J.; Vadas, M. A. An oncogenic role of sphingosine kinase. Curr. Biol., 2000, 10, 1527-1530.
75. Sarkar, S.; Maceyka, M.; Hait, N. C.; Paugh, S. W.; Sankala, H.; Milstien, S.; Spiegel, S. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett., 2005, 579, 5313-5317.
76. Pitman, M. R.; Pitson, S. M. Inhibitors of the sphingosine kinase pathway as potential therapeutics, Curr. Cancer Drug Targets, 2010, 10, 354-367.
77. Pyne, N. J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10, 489-503.
78. Chi, H. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol. Sci., 2011, 32, 16-24.
79. Xiang, Y.; Asmussen, G.; Booker, M.; Hirth, B.; Kane Jr, J. L.; Liao, J.; Noson, K. D.; Yee, C. Discovery of novel sphingosine kinase 1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6119-6121.
80. Xiang, Y.; Hirth, B.; Kane, Jr., J. L.; Liao, J.; Noson, K. D.; Yee, C.; Asmussen, G.; Fitzgerald, M.; Klaus, C.; Booker, M. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg. Med. Chem. Lett., 2010, 20, 4550-4554.
81. Mathews, T. P.; Kennedy, A. J.; Kharel, Y.; Kennedy, P. C.; Nicoara, O.; Sunkara, M.; Morris, A. J.; Wamhoff, B. R.; Lynch, K. R.; Macdonald, T. L. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors, J. Med. Chem., 2010, 53, 2766-2778.
82. Kennedy, A. J.; Mathews, T. P.; Kharel, Y.; Field, S. D.; Moyer, M. L.; East, J. E.; Houck, J. D.; Lynch, K. R.; Macdonald, T. L. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J. Med. Chem., 2011, 54, 3524-3548.
83. French, K. J.; Schrecengost, R. S.; Lee, B. D.; Zhuang, Y.; Smith, S. N.; Eberly, J. L.; Yun, J. K.; Smith, C. D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63, 5962-5969.
84. Hengst, J. A.; Wang, X.; Sk, U. H.; Sharma, A. K.; Amin, S.; Yun, J. K. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg. Med. Chem. Lett., 2010, 20, 7498-7502.
85. Sharma, A. K.; Sk, U. H.; Gimbor, M. A.; Hengst, J. A.; Wang, X.; Yun, J.; Amin, S. Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. Eur. J. Med. Chem., 2010, 45, 4149-4156.
86. Mathew, T.; Cavallari, M.; Billich, A.; Bornancin, F.; Nussbaumer, P.; De Libero, G.; Vasella, A. 4,5,6-Trisubstituted piperidinones as conformationally restricted ceramide analogues: synthesis and evaluation as inhibitors of sphingosine and ceramide kinases and as NKT cell-stimulatory antigens. Chem. Biodivers., 2009, 6, 1688-1715.
87. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20, 95-102.
88. Maceyka, M.; Sankala, H.; Hait, N. C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.; Merrill, A. H.; Milstien, Jr., S.; Spiegel, S. Sphk1 and Sphk2: Sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280, 37118-37129.
89. French, K. J.; Zhuang, Y.; Maines, L. W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J. J.; Green, C. L.; Keller, S. N.; Smith, C. D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther., 2010, 333, 129-139.
90. Beljanski, V.; Knaak, C.; Smith, C. D. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J. Pharmacol. Exp. Ther., 2010, 333, 454-464.
91. Chumanevich, A. A.; Poudyal, D.; Cui, X.; Davis, T.; Wood, P. A.; Smith, C. D.; Hofseth, L. J. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis, 2010, 31, 1787-1793.
92. Antoon, J. W.; White, M. D.; Slaughter, E. M.; Davis, J. L.; Khalili, H. S.; Elliott, S.; Smith, C. D.; Burow, M. E.; Beckman, B. S. Targeting NF-kB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther., 2011, 11, 678-689.
93. Beljanski, V.; Knaak, C.; Zhuang, Y.; Smith, C. D. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib, Invest. New Drug., 2010, 29, 1132-1142.
94. Kim, J. W.; Kim, Y. W.; Inagaki, Y.; Hwang, Y. A.; Mitsutake, S.; Ryu, Y. W.; Lee, W. K.; Ha, H. J.; Park, C. S.; Igarashi, Y. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg. Med. Chem., 2005, 13, 3475-3485.
95. Bornancin, F. Ceramide kinase: the first decade. Cell Signal. 2011, 23, 999-1008.
96. Graf, C.; Klumpp, M.; Habig, M.; Rovina, P.; Billich, A.; Baumruker, T.; Oberhauser, B.; Bornancin, F. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol. Pharmacol., 2008, 74, 925-932.
97. Hannun, Y. A.; Luberto, C. Lipid metabolism: ceramide transfer protein adds a new dimension. Curr. Biol., 2004, 14, 163-165.
98. Amtmann, E. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp. Clin. Res., 1996, 22, 287-294.
99. Gonzalez-Roura, A.; Casas, J.; Llebaria, A. Synthesis and phospholipase C inhibitory activity of D609 diastereomers. Lipids, 2002, 37, 401-406.
100. Meng, A.; Luberto, C.; Meier, P.; Bai, A.; Yang, X.; Hannun, Y. A.; Zhou, D. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp. Cell Res., 2004, 292, 385-392.
101. Bai, A.; Meier, G. P.; Wang, Y.; Luberto, C.; Hannun, Y. A.; Zhou, D. Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]- decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells. J. Pharmacol. Exp. Ther., 2004, 309, 1051-1059.
102. Ledroit, V.; Debitus, C.; Lavaud, C.; Massiot, G. Jaspines A and B: two new cytotoxic sphingosine derivatives from the marine sponge Jaspis sp., Tetrahedron Lett., 2003, 44, 225-228.
103. Salma, Y.; Lafont, E.; Therville, N.; Carpentier, S.; Bonnafe, M. J.; Levade, T.; Genisson, Y.; Andrieu-Abadie, N. The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochem. Pharmacol., 2009, 78, 477-485.
104. Canals, D.; Perry, D. M.; Jenkins, R. W.; Hannun, Y. A. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br. J. Pharmacol., 2011, 163, 694-712.
105. Luberto, C.; Hassler, D. F.; Signorelli, P.; Okamoto, Y.; Sawai, H. Boros, E.; Hazen-Martin, D. J.; Obeid, L. M.; Hannun, Y. A.; Smith, G. K. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase, J. Biol. Chem., 2002, 277, 41128-41139.
106. Yokomatsu, T.; Murano, T.; Akiyama, T.; Koizumi, J.; Shibuya, S.; Tsuji, Y.; Soeda, S.; Shimeno, H. Synthesis of non-competitive inhibitors of sphingomyelinases with significant activity. Bioorg. Med. Chem. Lett., 2003, 13, 229-236.
107. Yamagishi, T.; Muronoi, S.; Hikishima, S.; Shimeno, H.; Soeda, S.; Yokomatsu, T. Diastereoselective synthesis of gamma-Aminodelta-hydroxy-alpha,alpha-difluorophosphonates: A vehicle for structure-activity relationship studies on SMA-7, a potent sphingomyelinase inhibitor. J. Org. Chem., 2009, 74, 6350-6353.
108. Imagawa, H.; Oda, M.; Takemoto, T.; Yamauchi, R.; Yoshikawa, T.; Yamamoto, H.; Nishizawa, M.; Takahashi, H.; Hashimoto, M.; Yabiku, K.; Nagahama, M.; Sakurai, J. Synthesis and evaluation of novel phosphate ester analogs as neutral sphingomyelinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 3868-3871.
109. Lee, D. H.; Kim, S. H.; Ahn, K. H.; Kim, S. K.; Choi, J. M.; Ji, J. J. E.; Won, H.; Park, Y. H.; Lim, C.; Kim, S.; Kim, D. K. Identification and evaluation of neutral sphingomyelinase 2 inhibitors, Arch. Pharm. Res., 2011, 34, 229-236.
110. Smith, E. L.; Schuchman, E. H. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. Faseb J., 2008, 22, 3419-3431.
111. Prinetti, A.; Millimaggi, D.; D'Ascenzo, S.; Clarkson, M.; Bettiga, A.; Chigorno, V.; Sonnino, S.; Pavan, A.; Dolo, V. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem. J., 2006, 395, 311-318.
112. Lacour, S.; Hammann, A.; Grazide, S.; Lagadic-Gossmann, D.; Athias, A.; Sergent, O.; Laurent, G.; Gambert, P.; Solary, E.; Dimanche-Boitrel, M. T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res., 2004, 64, 3593-3598.
113. Arenz, C. Small molecule inhibitors of acid sphingomyelinase. Cell Physiol. Biochem., 2010, 26, 1-8.
114. Kornhuber, J.; Tripal, P.; Reichel, M.; Muhle, C.; Rhein, C.; Muehlbacher, M.; Groemer, T. W.; Gulbins, E. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol. Biochem., 2010, 26, 9-20.
115. Li, M.; Song, L.; Qin, X. Glycan changes: cancer metastasis and anti-cancer vaccines. J. Biosci., 2010, 35, 665-673.
116. Gouaze-Andersson, V.; Cabot, M. C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta, 2006, 1758, 2096-2103.
117. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627.
118. Sparreboom, A.; van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 2031-2035.
119. Chaudhary, P. M.; Roninson, I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst., 1993, 85, 632-639.
120. Lavie, Y.; Cao, H.; Volner, A.; Lucci, A.; Han, T. Y.; Geffen, V.; Giuliano, A. E.; Cabot, M. C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem., 1997, 272, 1682-1687.
121. Lucci, A.; Cho, W. I.; Han, T. Y.; Giuliano, A. E.; Morton, D. L.; Cabot, M. C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res., 1998, 18, 475-480.
122. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem., 1999, 274, 1140-1146.
123. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Hansen, N.; Cabot, M. C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem., 2000, 275, 7138-7143.
124. Wennekes, T.; van den Berg, R. J.; Boot, R. G.; van der Marel, G. A.; Overkleeft, H. S.; Aerts, J. M. Glycosphingolipids--nature, function, and pharmacological modulation. Angew. Chem. Int. Ed., 2009, 48, 8848-8869.
125. Gouaze, V.; Liu, Y. Y.; Prickett, C. S.; Yu, J. Y.; Giuliano, A. E.; Cabot, M. C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res., 2005, 65, 3861-3867.
126. Sietsma, H.; Veldman, R. J.; Kolk, D.; Ausema, B.; Nijhof, W.; Kamps, W.; Vellenga, E.; Kok, J. W. 1-phenyl-2-decanoylamino3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res., 2000, 6, 942-948.
127. Olshefski, R. S.; Ladisch, S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int. J. Cancer, 2001, 93, 131-138.
128. Maurer, B. J.; Metelitsa, L. S.; Seeger, R. C.; Cabot, M. C.; Reynolds, C. P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst., 1999, 91, 1138-1146.
129. Liu, Y-Y.; Han, T. Y.; Yu, Y. J.; Bitterman, A.; Le, A.; Giuliano, A. E.; Cabot, M. C. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res., 2004, 45, 933-940.
130. Norris-Cervetto, E.; Callaghan, R.; Platt, F. M.; Dwek, R. A.; Butters, T. D. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J. Biol. Chem., 2004, 279, 40412-40418.
131. Chai, L.; McLaren, R. P.; Byrne, A.; Chuang, W. L.; Huang, Y.; Dufault, M. R.; Pacheco, J.; Madhiwalla, S.; Zhang, X.; Zhang, M.; Teicher, B. A.; Carter, K.; Cheng, S. H.; Leonard, J. P.; Xiang, Y.; Vasconcelles, M.; Goldberg, M. A.; Copeland, D. P.; Klinger, K. W.; Lillie, J.; Madden, S. L.; Jiang, Y. A. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int. J. Oncol., 2011, 38, 701-711.
132. Liu, Y. Y.; Patwardhan, G. A.; Bhinge, K.; Gupta, V.; Gu, X.; Jazwinski, S. M. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res., 2011, 71, 2276-2285.
133. Chatterjee, S.; Pandey, A. The yin and yang of lactosylceramide metabolism: implications in cell function. BBA-Gen Subjects, 2008, 1780, 370-382.
134. Chatterjee, S.; Kolmakova, A.; Rajesh, M. Regulation of lactosylceramide synthase (glucosylceramide beta1-->4 galactosyltransferase); implication as a drug target. Curr. Drug Targets, 2008, 9, 272-281.
135. Rajesh, M.; Kolmakova, A.; Chatterjee, S. Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells. Circ. Res., 2005, 97, 796-804.
136. Kakugawa, Y.; Wada, T.; Yamaguchi, K.; Yamanami, H.; Ouchi, K., Sato, I.; Miyagi, T. Up-regulation of plasma membraneassociated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. USA, 2002, 99, 10718-10723.
137. Chatterjee, S.; Cleveland, T.; Shi, W. Y.; Inokuchi, J.; Radin, N. S. Studies of the action of ceramide-like substances (Dand L-PDMP) on sphingolipid glycosyltransferases and purified lactosylceramide synthase. Glycoconj J., 1996, 13, 481-486.
138. Radin, N. S.; Shayman, J. A.; Inokuchi, J. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv. Lipid Res., 1993, 26, 183-213.
139. Kamani, M.; Mylvaganam, M.; Tian, R.; Rigat, B.; Binnington, B.; Lingwood, C. Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J. Biol. Chem., 2011, 286, 21413-21426.
140. Garcia-Alvarez, I.; Corrales, G.; Doncel-Perez, E.; Munoz, A.; Nieto-Sampedro, M.; Fernandez-Mayoralas, A. Design and synthesis of glycoside inhibitors of glioma and melanoma growth. J. Med. Chem., 2007, 50, 364-373.
141. Garcia-Alvarez, I.; Egido-Gabas, M.; Romero-Ramirez, L.; Doncel-Perez, E.; Nieto-Sampedro, M.; Casas, J.; Fernandez-Mayoralas, A. Lipid and ganglioside alterations in tumor cells treated with antimitotic oleyl glycoside. Mol. Biosyst., 2011, 7, 129-138.
142. van Veldhoven, P. P.; Mannaerts, G. P. Sphingosine-phosphate lyase. Adv. Lipid Res., 1993, 26, 69-98.
143. Bourquin, F.; Riezman, H.; Capitani, G.; Grutter, M. G. Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure, 2010, 18, 1054-1065.
144. Kumar, A.; Saba, J. D. Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert. Opin. Ther. Targets, 2009, 13, 1013-1025.
145. Colie, S.; Van Veldhoven, P. P.; Kedjouar, B.; Bedia, C.; Albinet, V.; Sorli, S. C.; Garcia, V.; Djavaheri-Mergny, M.; Bauvy, C.; Codogno, P.; Levade, T.; Andrieu-Abadie, N. Disruption of Sphingosine 1-Phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation, Cancer Res., 2009, 69, 9346-9353.
146. Bagdanoff, J. T.; Donoviel, M. S.; Nouraldeen, A.; Tarver, J.; Fu, Q.; Carlsen, M.; Jessop, T. C.; Zhang, H.; Hazelwood, J.; Nguyen, H.; Baugh, S. D.; Gardyan, M.; Terranova, K. M.; Barbosa, J.; Yan, J.; Bednarz, M.; Layek, S.; Courtney, L. F.; Taylor, J.; Digeorge-Foushee, A. M.; Gopinathan, S.; Bruce, D.; Smith, T.; Moran, L.; O'Neill, E.; Kramer, J.; Lai, Z.; Kimball, S. D.; Liu, Q.; Sun, W.; Yu, S.; Swaffield, J.; Wilson, A.; Main, A.; Carson, K. G.; Oravecz, T.; Augeri, D. J. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J. Med. Chem., 2009, 52, 3941-3953.
147. Bagdanoff, J. T.; Donoviel, M. S.; Nouraldeen, A.; Carlsen, M.; Jessop, T. C.; Tarver, J.; Aleem, S.; Dong, L.; Zhang, H.; Boteju, L.; Hazelwood, J.; Yan, J.; Bednarz, M.; Layek, S.; Owusu, I. B.; Gopinathan, S.; Moran, L.; Lai, Z.; Kramer, J.; Kimball, S. D.; Yalamanchili, P.; Heydorn, W. E.; Frazier, K. S.; Brooks, B.; Brown, P.; Wilson, A.; Sonnenburg, W. K.; Main, A.; Carson, K. G.; Oravecz, T.; Augeri, D. J. Inhibition of sphingosine 1-Phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J. Med. Chem., 2010, 53, 8650-8662.
148. Antoon, J. W.; Liu, J.; Gestaut, M. M.; Burow, M. E.; Beckman, B. S.; Foroozesh, M. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J. Med. Chem., 2009, 52, 5748-5752.
149. Antoon, J. W.; Liu, J.; Ponnapakkam, A. P.; Gestaut, M. M.; Foroozesh, M.; Beckman, B. S. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol., 2010, 65, 1191-1195.
150. Liu, J.; Antoon, J. W.; Ponnapakkam, A.; Beckman, B. S.; Foroozesh, M. Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorg. Med. Chem., 2010, 18, 5316-5322.
151. Bieberich, E.; Kawaguchi, T.; Yu, R. K. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J. Biol. Chem., 2000, 275, 177-181.
152. Bieberich, E.; Hu, B.; Silva, J.; MacKinnon, S.; Yu, R. K.; Fillmore, H.; Broaddus, W. C.; Ottenbrite, R. M. Synthesis and characterization of novel ceramide analogs for induction of apoptosis in human cancer cells. Cancer Lett., 2002, 181, 55-64.
153. Oh, J. E.; So, K. S.; Lim, S. J.; Kim, M. Y. Induction of apoptotic cell death by a ceramide analog in PC-3 prostate cancer cells. Arch. Pharm. Res., 2006, 29, 1140-1146.
154. Bittman, R.; Li, Z.; Samadder, P.; Arthur, G. Anticancer activity of a ceramide analog containing a disulfide linkage. Cancer Lett., 2007, 251, 53-58.
155. Crawford, K. W.; Bittman, R.; Chun, J.; Byun, H. S.; Bowen, W. D. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol. Biol., 2003, 49, 1017-1023.
156. Shabbits, J. A.; Mayer, L. D. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res., 2003, 23, 3663-3669.
157. Stover, T. C.; Sharma, A.; Robertson, G. P.; Kester, M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res., 2005, 11, 3465-3474.
158. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S. F.; Kaiser, J.; Shanmugavelandy, S. S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K. T.; Jarbadan, N. R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T. J.; Kester, M.; Jr. Loughran, T. P.; Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116, 4192-4201.
159. Tran, M. A.; Smith, C. D.; Kester, M.; Robertson, G. P. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res., 2008, 14, 3571-3581.
160. Johnson, C. R.; Chun, J.; Bittman, R.; Jarvis, W. D. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells. J. Pharmacol. Exp. Ther., 2004, 309, 452-461.
161. Canals, D.; Mormeneo, D.; Fabrias, G.; Llebaria, A.; Casas, J.; Delgado, A. Synthesis and biological properties of Pachastrissamine (jaspine B) and diastereoisomeric jaspines. Bioorg. Med. Chem., 2009, 17, 235-241.
162. Dragusin, M.; Gurgui, C.; Schwarzmann, G.; Hoernschemeyer, J.; van Echten-Deckert, G. Metabolism of the unnatural anticancer lipid safingol, L-threo-dihydrosphingosine, in cultured cells. J. Lipid Res., 2003, 44, 1772-1779.
163. Noda, T.; Iwai, S.; Hamada, M.; Fujita, Y.; Yura, Y. Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G. Apoptosis, 2009, 14, 287-297.
164. Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz-Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H.; Schwartz, Jr., G. K. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy, 2009, 5, 184-193.
165. Schwartz, G. K.; Ward, D.; Saltz, L.; Casper, E. S.; Spiess, T.; Mullen, E.; Woodworth, J.; Venuti, R.; Zervos, P.; Storniolo, A. M.; Kelsen, D. P. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res., 1997, 3, 537-543.
166. Villorbina, G.; Canals, D.; Carde, L.; Grijalvo, S.; Pascual, R.; Rabal, O.; Teixido, J.; Fabrias, G.; Llebaria, A.; Casas, J.; Delgado, A. Solid-phase synthesis of a combinatorial library of dihydroceramide analogues and its activity in human alveolar epithelial cells. Bioorg. Med. Chem., 2007, 15, 50-62.
167. Maurer, B. J.; Melton, L.; Billups, C.; Cabot, M. C.; Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst., 2000, 92, 1897-1909.
168. Batra, S.; Reynolds, C. P.; Maurer, B. J. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res., 2004, 64, 5415-5424.
169. Ling, L. U.; Lin, H.; Tan, K. B.; Chiu, G. N. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int. J. Oncol., 2009, 35, 1463-1471.
170. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov., 2010, 9, 883-897.
171. Zemann, B.; Kinzel, B.; Muller, M.; Reuschel, R.; Mechtcheriakova, D.; Urtz, N.; Bornancin, F.; Baumruker, T.; Billich, A. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood, 2006, 107, 1454-1458.
172. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O'Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.; Wood, A.; Liau, G.; Billy, E.; Theuer, A.; Hla, T.; Wood, J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res., 2006, 66, 221-231.
173. Schmid, G.; Guba, M.; Ischenko, I.; Papyan, A.; Joka, M.; Schrepfer, S.; Bruns, C. J.; Jauch, K. W.; Heeschen, C.; Graeb, C. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell Biochem., 2007, 101, 259-270.
174. Wang, J. D.; Takahara, S.; Nonomura, N.; Ichimaru, N.; Toki, K.; Azuma, H.; Matsumiya, K.; Okuyama, A.; Suzuki, S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate, 1999, 40, 50-55.
175. Azuma, H.; Horie, S.; Muto, S.; Otsuki, Y.; Matsumoto, K.; Morimoto, J.; Gotoh, R.; Okuyama, A.; Suzuki, S.; Katsuoka, Y.; Takahara, S. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res., 2003, 23, 3183-3193.
176. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol., 2003, 169, 2372-2377.
177. Sonoda, Y.; Yamamoto, D.; Sakurai, S.; Hasegawa, M.; Aizu-Yokota, E.; Momoi, T.; Kasahara, T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun., 2001, 281, 282-288.
178. Berdyshev, E. V.; Gorshkova, I.; Skobeleva, A.; Bittman, R.; Lu, X.; Dudek, S. M.; Mirzapoiazova, T.; Garcia, J. G.; Natarajan, V. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem., 2009, 284, 5467-5477.
179. Lim, K. G. F. Tonelli, Z. Li, X. Lu, R. Bittman, S. Pyne, N. J. Pyne, FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem., 2011, 286, 18640.
180. Dawson, G.; Qin, J. Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochem. Biophys. Res. Commun., 2011, 404, 321-323.
181. Symolon, H.; Schmelz, E. M.; Dillehay, D. L.; Jr., Merrill, A. H.; Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J. Nutr., 2004, 134, 1157-1161.
182. Sugawara, T.; Zaima, N.; Yamamoto, A.; Sakai, S.; Noguchi, R.; Hirata, T. Isolation of sphingoid bases of sea cucumber cerebrosides and their cytotoxicity against human colon cancer cells. Biosci. Biotechnol. Biochem., 2006, 70, 2906-2912.
183. Struckhoff, A. P.; Bittman, R.; Burow, M. E.; Clejan, S.; Elliott, S.; Hammond, T.; Tang, Y.; Beckman, B. S. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther., 2004, 309, 523-532.
184. Fyrst, H.; Zhang, X.; Herr, D. R.; Byun, H. S.; Bittman, R.; Phan, V. H.; Harris, G. L.; Saba, J. D. Identification and characterization by electrospray mass spectrometry of endogenous Drosophila sphingadienes. J. Lipid Res., 2007.
185. Fyrst, H.; Oskouian, B.; Bandhuvula, P.; Gong, Y.; Byun, H. S.; Bittman, R.; Lee, A. R.; Saba, J. D. Natural sphingadienes inhibit Akt-Dependent signaling and prevent intestinal tumorigenesis. Cancer Res., 2009, 69, 9457-9464.
186. Bertea, M.; Rutti, M. F.; Othman, A.; Marti-Jaun, J.; Hersberger, M.; von Eckardstein, A.; Hornemann, T. Deoxysphingoid bases as plasma markers in Diabetes mellitus. Lipids in Health and Disease 2010, 9, article # 84.
187. Eichler, F. S.; Hornemann, T.; McCampbell, A.; Kuljis, D.; Penno, A.; Vardeh, D.; Tamrazian, E.; Garofalo, K.; Lee, H. J.; Kini, L.; Selig, M.; Frosch, M.; Gable, K.; von Eckardstein, A.; Woolf, C. J.; Guan, G.; Harmon, J. M.; Dunn, T. M.; Brown, R. H. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J. Neurosci., 2009, 29, 14646-14651.
188. Zitomer, N. C.; Mitchell, T.; Voss, K. A.; Bondy, G. S.; Pruett, S. T.; Garnier-Amblard, E. C.; Liebeskind, L. S.; Park, H.; Wang, E.; Sullards, M. C.; Merrill, A. H.; Riley, Jr., R. T. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: A novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J. Biol. Chem., 2009, 284, 4786-4795.
189. Stokvis, E.; Nan-Offeringa, L.; Rosing, H.; Lopez-Lazaro, L.; Acena, J. L.; Miranda, E.; Lyubimov, A.; Levine, B. S.; D'Aleo, C.; Schellens, J. H. M.; Beijnen, J. H.; Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. J. Mass Spectrom., 2003, 38, 548-554.
190. Cuadros, R.; Montejo de Garcini, E.; Wandosell, F.; Faircloth, G.; Fernandez-Sousa, J. M.; Avila, J. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett., 2000, 152, 23-29.
191. Singh, R.; Sharma, M.; Joshi, P.; Rawat, D. S. Clinical status of anti-cancer agents derived from marine sources. Anti-Cancer Agents Med. Chem., 2008, 8, 603-617.
192. Sanchez, A. M.; Malagarie-Cazenave, S.; Olea, N.; Vara, D.; Cuevas, C.; Diaz-Laviada, I. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur. J. Pharmacol. 2008, 584, 237-245.
193. Humpf, H.-U.; Schmelz, E.-M.; Meredith, F. I.; Vesper, H.; Vales, T. R.; Wang, E.; Menaldino, D. S.; Liotta, D. C.; Merrill Jr., A. H. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. J. Biol. Chem., 1998, 273, 19060-19064.
194. Williams, R. Discontinued drugs in 2008: oncology drugs. Expert Opinion on Investigational Drugs, 2009, 18, 1581-1594.
195. Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S. G.; Allegood, J. C.; Pruett, S. T.; Sullards, M. C.; Dillehay, D. L.; Liotta, D. C.; Merrill, A. H. Enigmol: A novel sphingolipid analog with anti-cancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer. Mol. Cancer Ther., 2011, 10, 648-657.
196. Garnier-Amblard, E. C.; Mays, S. G.; Arrendale, R. F.; Baillie, M. T.; Bushnev, A. S.; Culver, D. G.; Evers, T. J.; Holt, J. J.; Howard, R. B.; Liebeskind, L. S.; Menaldino, D. S.; Natchus, M. G.; Petros, J. A.; Ramaraju, H.; Reddy, G. P.; Liotta, D. C. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. ACS Medicinal Chemistry Letters 2011, 2, 438-443.
197. Berkers, C. R.; Ovaa, H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci., 2005, 26, 252-257.
198. Natori, T.; Koezuka, Y.; Higa, T. Agelasphins, novel alphagalactosylceramides from the marine sponge Agelas mauritianus, Tetrahedron Lett., 1993, 34, 5591-5592.
199. Natori, T.; Morita, M.; Akimoto, K.; Koezuka, Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus. Tetrahedron, 1994, 50, 2771-2784.
200. Wilson, S. B.; Delovitch, T. L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol., 2003, 3, 211-222.
201. Wu, D.; Fujio, M.; Wong, C. H. Glycolipids as immunostimulating agents. Bioorg. Med. Chem., 2008, 16, 1073-1083.
202. Cerundolo, V.; Silk, J. D.; Masri, S. H.; Salio, M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol., 2009, 9, 28-38.
203. Berzofsky, J. A.; Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med., 2009, 9, 667-672.
204. Van Kaer, L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol., 2005, 5, 31-42.
205. Fujii, S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol., 2008, 29, 242-249.
206. Huwiler, A.; Pfeilschifter, J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem. Pharmacol., 2008, 75, 1893-1900.
207. Visentin, B.; Vekich, J. A.; Sibbald, B. J.; Cavalli, A. L.; Moreno, K. M.; Matteo, R. G.; Garland, W. A; Lu, Y.; Yu, S.; Hall, H. S.; Kundra, V.; Mills, G. B.; Sabbadini, R. A. Validation of an antisphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9, 225-238.
208. O'Brien, N.; Jones, S. T.; Williams, D. G.; Cunningham, H. B.; Moreno, K.; Visentin, B.; Gentile, A.; Vekich, J.; Shestowsky, W.; Hiraiwa, M.; Matteo, R.; Cavalli, A.; Grotjahn, D.; Grant, M.; Hansen, G.; Campbell, M. A.; Sabbadini, R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J. Lipid Res., 2009, 50, 2245-2257.
209. Chintalapati, M.; Truax, R.; Stout, R.; Portier, R.; Losso, J. N. In Vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate. J. Agric. Food Chem., 2009, 57, 5201-5210.
210. Bedia, C.; Levade, T.; Codogno, P. Regulation of autophagy by sphingolipids. Anticancer Agents Med. Chem., 2011, 11(9):844-53.
211. Garber, K.; Inducing indigestion: companies embrace autophagy inhibitors. J. Natl. Cancer Inst., 2011, 103, 708-710.
212. Fleming, A.; Noda, T.; Yoshimori, T.; Rubinsztein, D. C. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat. Chem. Biol., 2011, 7, 9-17.
213. Wu, L.; Yan, B. Discovery of small molecules that target autophagy for cancer treatment. Curr. Med. Chem., 2011, 18, 1866-1873.
214. Iorio, F.; Isacchi, A.; di Bernardo, D.; Brunetti-Pierri, N. Identification of small molecules enhancing autophagic function from drug network analysis. Autophagy, 2010, 6, 1204-1205.
215. Alphonse, G.; Bionda, C.; Aloy, M. T.; Ardail, D.; Rousson, R.; Rodriguez-Lafrasse, C. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene, 2004, 23, 2703-2715.